We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -15.00 | -0.91% | 1,636.00 | 1,638.00 | 1,639.00 | 1,661.50 | 1,635.50 | 1,656.50 | 4,329,161 | 16:35:12 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.69 | 67.46B |
From Apr 2019 to Apr 2024
LONDON--Vectura Group PLC (VEC.LN) said on Wednesday it has filed a patent infringement lawsuit against GlaxoSmithKline PLC (GSK.LN) because GSK didn't exercise the option to license any additional patents under an agreement with Vectura dated August 2010.
Vectura, which specialises in products for inhaled airways disease, also reiterated its 2016 revenue guidance.
The lawsuit claims infringement of one of Vectura's patents in the U.S., the company said. The separate agreement with GSK relating to the legacy Skyepharma dry powder formulation technology used in GSK's Ellipta product range is unaffected by this lawsuit, Vectura said.
In August of 2010, GSK and Vectura entered a license and option-to-licence agreement relating to a number of Vectura patent families and various formulation technologies relevant to the Ellipta products.
Vectura shares at 1630 GMT up 0.20 pence, or 0.1%, at 150 pence, while GSK shares up 29.50 pence, or 1.8%, at 1,696.50 pence.
Write to Olga Cotaga at olga.cotaga@wsj.com, Twitter @OlgaCotaga
(END) Dow Jones Newswires
July 27, 2016 13:01 ET (17:01 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
